[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurotoxicity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurotoxicity":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,37,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":36},"100527160","a-pilot-study-for-pupillary-assessment-to-predict-car-t-related-neurotoxicity-100527160",false,"NCT06144151","A Pilot Study for Pupillary Assessment to Predict CAR-T Related Neurotoxicity","Inclusion Criteria:\n\nTo be considered eligible for study participation, patient will satisfy all relevant inclusion criteria and none of the exclusion criteria.\n\nInclusion Criteria:\n\n1. Ages Eligible for Study: 18 Years and above (Adult, Older Adult)\n2. Sexes Eligible for Study: All\n3. Patient with histologically proven DLBCL, PMBCL or tFL, or follicular Lymphoma receiving axi-cel CAR-T cell therapy in the inpatient setting at MD Anderson Cancer Center\n4. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Patients who have already been administered CAR-T cell therapy.\n2. The patient who is unwilling or unable to comply with the requirements of the study including being able to be assessed with pupillometer\n3. Patient has a condition which places him at an unacceptable risk as determined by the investigator","ALL","18 Years",{"count":18,"type":19},100,"ESTIMATED","OBSERVATIONAL","To learn about the relationship between changes in pupil size and reactivity and the start of neurological side effects in patients after receiving CAR-T cell therapy.",[23],"Neurotoxicity","RECRUITING","2026-04-13",{"date":27,"type":28},"2026-04-16","ACTUAL",{"date":30,"type":28},"2024-02-08",{"date":32,"type":19},"2027-04-01",{"name":34,"class":35},"M.D. Anderson Cancer Center","OTHER",1,{"id":38,"slug":39,"hasResults":11,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":4,"eligibilityCriteria":43,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":44,"targetDuration":4,"studyType":46,"phases":47,"briefSummary":49,"conditions":50,"keywords":54,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":36},"100623990","assessing-dcog-short-for-neurotoxicity-in-car-t-100623990","NCT07403812","Assessing DCog Short for Neurotoxicity in CAR-T","Assessing the Performance of \"DCog Short\", an iPad-Based Tool for Neurotoxicity Evaluation in CAR-T Cell Therapy Patients: A Pilot Study","Inclusion Criteria:\n\n* participants treated with CART-Cell therapy as described above and therefore at risk for treatment associated neurotoxicity.\n* Visual acuity of 20\u002F100 or better.\n\nExclusion Criteria:\n\n* patients \\\u003C 18 years old\n* pregnant women\n* prisoners\n* adults unable to consent,\n* participants unwilling to use iPad-based tools. Severe motor deficits that can prevent patients from using an iPad",{"count":45,"type":19},40,"INTERVENTIONAL",[48],"NA","The aim of this study is to determine the effectiveness of DCog Short, a self-reporting, iPad-based application tool, in assessing neurotoxicity in participants undergoing CAR-T cell therapy.",[23,51,52,53],"Neurotoxicity Syndromes","Hematologic Malignancy","Immune Effector Cell Associated Neurotoxicity Syndrome",[23,55,52,53],"Neurotoxicity Syndrome","NOT_YET_RECRUITING","2026-02-04",{"date":59,"type":28},"2026-02-11",{"date":61,"type":19},"2026-07",{"date":63,"type":19},"2027-08-31",{"name":65,"class":35},"Beth Israel Deaconess Medical Center",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":46,"phases":76,"briefSummary":78,"conditions":79,"keywords":84,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":36},"100446143","phase-4-tacrolimus-associated-tremors-in-liver-transplantation-immediate-release-versus-extended-release-formulations-100446143","NCT05089604","Tacrolimus Associated Tremors in Liver Transplantation: Immediate-Release Versus Extended-Release Formulations","Tacrolimus Associated Tremors in Liver Transplant Recipients: a Randomized Open Label Trial Comparing De Novo Extended-release Once Daily (LCP-TAC) and Twice Daily Immediate-release (IR-TAC) Tacrolimus Formulations","LCP-TAC","Inclusion Criteria:\n\n1. Adults aged 18 years or older\n2. Recipients of a first-time liver transplant\n3. eGFR more than 30 ml\u002Fmin on the day of tacrolimus initiation\n4. All patients who are eligible to initiate Tacrolimus within 7 days post-liver transplant\n5. Informed consent\n\nExclusion Criteria:\n\n1. Recipients of prior organ transplant\n2. Need for hemodialysis either prior or following liver transplantation\n3. Recipients of living donor liver or split deceased donor liver allografts\n4. Recipients of combined liver\u002Fkidney transplants\n5. Recipients receiving liver allografts from donors with HCV viremia (detected through nucleic acid testing or other means)\n6. Patients with a history of tremor prior to transplantation including essential tremors, Parkinson's or Parkinsonian syndromes\n7. Patients receiving concomitant medications known to induce tremors such as dopamine blocking agents\n8. Baseline TSH, T3, T4 indicating hyperthyroidism",{"count":75,"type":19},124,[77],"PHASE4","This is a randomized open label study in de novo liver transplant recipients that aims to compare the risk of tacrolimus induced tremors with once daily extended-release formulation, Envarsus, versus the twice daily immediate-release formulation. Both formulations of tacrolimus are currently approved for the prevention of rejection in liver transplant patients.",[80,81,23,82,83],"Liver Transplantation","Immunosuppression","Tremor","Tacrolimus",[85,83,81,82,86,72,23],"Liver Transplant","Envarsus","2023-12-27",{"date":89,"type":28},"2024-01-02",{"date":91,"type":28},"2023-01-09",{"date":93,"type":19},"2026-12-31",{"name":95,"class":35},"University of British Columbia"]